- Home
- RMCF vs PHIO Comparison
RMCF vs PHIO Comparison
Compare RMCF & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- PHIO
- Stock Information
- Founded
- RMCF 1981
- PHIO 2011
- Country
- RMCF United States
- PHIO United States
- Employees
- RMCF N/A
- PHIO N/A
- Industry
- RMCF Specialty Foods
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- PHIO Health Care
- Exchange
- RMCF Nasdaq
- PHIO Nasdaq
- Market Cap
- RMCF 11.4M
- PHIO 12.1M
- IPO Year
- RMCF N/A
- PHIO N/A
- Fundamental
- Price
- RMCF $1.67
- PHIO $1.62
- Analyst Decision
- RMCF
- PHIO Strong Buy
- Analyst Count
- RMCF 0
- PHIO 3
- Target Price
- RMCF N/A
- PHIO $10.67
- AVG Volume (30 Days)
- RMCF 140.9K
- PHIO 8.1M
- Earning Date
- RMCF 10-13-2025
- PHIO 11-11-2025
- Dividend Yield
- RMCF N/A
- PHIO N/A
- EPS Growth
- RMCF N/A
- PHIO N/A
- EPS
- RMCF N/A
- PHIO N/A
- Revenue
- RMCF $29,988,000.00
- PHIO N/A
- Revenue This Year
- RMCF N/A
- PHIO N/A
- Revenue Next Year
- RMCF N/A
- PHIO N/A
- P/E Ratio
- RMCF N/A
- PHIO N/A
- Revenue Growth
- RMCF 8.09
- PHIO N/A
- 52 Week Low
- RMCF $1.12
- PHIO $0.97
- 52 Week High
- RMCF $3.18
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- RMCF 49.29
- PHIO 22.16
- Support Level
- RMCF $1.48
- PHIO $2.08
- Resistance Level
- RMCF $1.85
- PHIO $4.19
- Average True Range (ATR)
- RMCF 0.12
- PHIO 0.26
- MACD
- RMCF -0.00
- PHIO -0.05
- Stochastic Oscillator
- RMCF 49.43
- PHIO 0.58
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.